- Home
- MNMD
as of 12-05-2025 4:00pm EST
$12.35
$0.08
-0.64%
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
Chart Type:
Time Range:
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 960.2M | IPO Year: | N/A |
| Target Price: | $25.78 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.70 - $14.43 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered MNMD Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 73.03%
73.03%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Mind Medicine (MindMed) Inc. (MNMD)
Sullivan Mark
Sell
Chief Legal Officer
MNMD Sep 25, 2025
Avg Cost/Share
$9.77
Shares
11,278
Total Value
$110,186.06
Owned After
293,852
SEC Form 4
Barrow Robert
Sell
Chief Executive Officer
MNMD Sep 25, 2025
Avg Cost/Share
$9.77
Shares
25,797
Total Value
$252,036.69
Owned After
804,268
SEC Form 4
Karlin Dan
Sell
Chief Medical Officer
MNMD Sep 25, 2025
Avg Cost/Share
$9.77
Shares
7,704
Total Value
$75,268.08
Owned After
430,625
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Sullivan Mark | MNMD | Chief Legal Officer | Sep 25, 2025 | Sell | $9.77 | 11,278 | $110,186.06 | 293,852 | |
| Barrow Robert | MNMD | Chief Executive Officer | Sep 25, 2025 | Sell | $9.77 | 25,797 | $252,036.69 | 804,268 | |
| Karlin Dan | MNMD | Chief Medical Officer | Sep 25, 2025 | Sell | $9.77 | 7,704 | $75,268.08 | 430,625 |
Latest Mind Medicine (MindMed) Inc. News
MNMD Breaking Stock News: Dive into MNMD Ticker-Specific Updates for Smart Investing
Compare MNMD vs Leading Stocks
See how MNMD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MNMD Mind Medicine (MindMed) Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.